Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 1, 2011, Pages 228-233

  Van Wijk, Jeroen P H ^a   Hoepelman, Andy I M ^a   De Koning, Eelco J P ^b   Dallinga Thie, Geesje ^c   Rabelink, Ton J ^b   Cabezas, Manuel Castro ^d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d SINT FRANCISCUS GASTHUIS   (Netherlands)

Author keywords

adipose tissue; atherosclerosis; HIV; insulin resistance; postprandial; triglycerides

Indexed keywords

FATTY ACID; HYDROXYBUTYRIC ACID; METFORMIN; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; HIV ASSOCIATED LIPODYSTROPHY; HOMEOSTASIS; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LOADING TEST; MALE; OPEN STUDY; POSTPRANDIAL STATE; PRIORITY JOURNAL;

AREA UNDER CURVE; BIOLOGICAL MARKERS; CHOLESTEROL; FATTY ACIDS, NONESTERIFIED; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYDROXYBUTYRATES; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; NETHERLANDS; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 78650885879     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.216192     Document Type: Article

References (48)

1. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62. (Pubitemid 40075680)
2. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS. 2003;17(suppl 1):S141-S148.
3. Stein JH. Dyslipidemia in the era of HIV protease inhibitors. Prog Cardiovasc Dis. 2003;45:293-304.
4. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
5. DAD Study Group; Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiébaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.
6. van Wijk JP, Castro Cabezas M, de Koning EJ, Rabelink TJ, van der Geest R, Hoepelman IM. In vivo evidence of impaired peripheral fatty acid trapping in patients with human immunodeficiency virus-associated lipodystrophy. J Clin Endocrinol Metab. 2005;90:3575-3582.
7. Stein JH, Merwood MA, Bellehumeur JB, McBride PE, Wiebe DA, Sosman JM. Postprandial lipoprotein changes in patients taking antiret- roviral therapy for HIV infection. Arterioscler Thromb Vasc Biol. 2005; 25:399-405.
8. Sekhar RV, Iyer D, Gaubatz J, Rehman K, Maldonado M, Pownall HJ, Visnegerwala F, Jahoor F, Balasubramanyam A. Marked impairment of dietary triglyceride disposal contributes to hypertriglyceridemia in HIV lipodystrophy syndrome. Antiviral Ther. 2003;8:L46.
9. Reeds DN, Mittendorfer B, Patterson BW, Powderly WG, Yarasheski KE, Klein S. Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol Endocrinol Metab. 2003;285:E490-E497.
10. Anuurad E, Thomas-Geevarghese A, Devaraj S, Albu J, Minolfo R, El-Sadr WM, Lu G, Karmally W, Berglund L. Increased lipoprotein remnant cholesterol levels in HIV-positive patients during antiretroviral therapy. Atherosclerosis. 2008;198:192-197.
11. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation. 2008;118:993-1001.
12. Weintraub MS, Grosskopf I, Rassin T, Miller H, Charach G, Rotmensch HH, Liron M, Rubinstein A, Iaina A. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. BMJ. 1996;312:935-939.
13. Patsch JR, Miesenböck G, Hopferwieser T, Mühlberger V, Knapp E, Dunn JK, Gotto AM Jr, Patsch W. Relation of triglyceride metabolism and coronary artery disease. Arterioscler Thromb. 1992;12:1336-1345.
14. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, Campos E. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta. 1993;223:53-71.
15. Twickler TB, Dallinga-Thie GM, Cohn JS, Chapman MJ. Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype. Circulation. 2004;109: 1918-1925.
16. Mamo JC, Proctor SD, Smith D. Retention of chylomicron remnants by arterial tissue: importance of an efficient clearance mechanism from plasma. Atherosclerosis. 1998;141(suppl 1):S63-S69.
17. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs. 2003;63:1879-1894.
18. Yki-Jarvinen H Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
19. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA. 2000;284:472-477.
20. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS. 1999;13:1000-1002.
21. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med. 2004;140:786-794.
22. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, Wand H, Law M, Samaras K, Emery S, Cooper DA; Rosey Investigators. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, doubleblind, placebo-controlled trial. Lancet. 2004;363:429-438.
23. van Wijk JP, de Koning EJ, Castro Cabezas M, op't Roodt J, Joven J, Rabelink TJ, Hoepelman IM. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med. 2005;143:337-346.
24. Sheth SH, Larson RJ. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis. 2010;10:183.
25. Borkan GA, Gerzof SG, Robbins AH, Hults DE, Silbert CK, Silbert JE. Assessment of abdominal fat content by computed tomography. Am J Clin Nutr. 1982;36:172-177.
26. Miles JM, Haymond MW, Nissen SL, Gerich JE. Effects of free fatty acid availability, glucagon excess, and insulin deficiency on ketone body production in postabsorptive man. J Clin Invest. 1983;71:1554-1561.
27. Visnegarwala F, Shi J, D'Amico S, Jahoor F, Rehman K, Ellis K. Effect of short-term rosiglitazone treatment on lipid kinetics in patients with HIV lipodystrophy syndrome. Antivir Ther. 2003;8:A52.
28. Tan GD, Fielding BA, Currie JM, Humphreys SM, Desage M, Frayn KN, Laville M, Vidal H, Karpe F. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia. 2005;48:83-95.
29. Juurinen L, Kotronen A, Granér M, Yki-Järvinen H. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses. J Clin Endocrinol Metab. 2008;93:118-124.
30. Jeppesen J, Zhou MY, Chen YD, Reaven GM. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care. 1994;17:1093-1099.
31. Grosskopf I, Ringel Y, Charach G, Maharshak N, Mor R, Iaina A, Weintraub M. Metformin enhances clearance of chylomicrons and chylomicron remnants in nondiabetic mildly overweight glucose-intolerant subjects. Diabetes Care. 1997;20:1598-1602.
32. van Wijk JP, de Koning EJ, Castro Cabezas M, Rabelink TJ. Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care. 2005;28:844-849.
33. Nissen SE, Wolski K. Effects of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356:2457-2471.
34. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298:1189-1195.
35. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170:1191-1201.
36. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373:2125-2135.
37. Mitka M. Critics press FDA to act on evidence of rosiglitazone's cardiac safety issues. JAMA. 2010;303:2341-2342.
38. James AP, Watts GF, Mamo JC. The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects. Diabetes Obes Metab. 2005;7:381-389.
39. Duez H, Lamarche B, Uffelman KD, Valéro R, Szeto L, Lemieux S, Cohn JS, Lewis GF. Dissociation between the insulin-sensitizing effect of rosiglitazone and its effect on hepatic and intestinal lipoprotein production. J Clin Endocrinol Metab. 2008;93:1722-1729.
40. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045-1052.
41. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.
42. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547-1554.
43. van Wijk JP, de Koning EJ, Martens EP, Rabelink TJ. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2003;23:1744-1749.
44. Berneis K, Rizzo M, Stettler C, Chappuis B, Braun M, Diem P, Christ ER. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with type 2 diabetes. Expert Opin Pharmacother. 2008;9:343-349.
45. Deeg MA, Tan MH. Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies. PPAR Res. 2008: Article ID 520465.
46. Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bensadoun A, Fruchart-Najib J, Holleran S, Cohn JS, Ramakrishnan R, Ginsberg HN. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest. 2005;115:1323-1332.
47. McGoldrick C, Leen CLS. The management of dyslipidaemias in antiretroviral-treated HIV infection: a systematic review. HIV Med. 2007; 8:325-334.
48. Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32:493-498.